Novo Nordisk has given up on two more phase 3 trials of ziltivekimab, further eroding the prospects for a molecule that analysts had once tipped as a potential blockbuster.
The Danish drugmaker had been evaluating the IL‑6 ligand in the late-stage Hermes and Athena trials, which enrolled 4,900 and 673 patients, respectively, with heart failure with mildly reduced or preserved ejection fraction. Success in both trials was to be judged by ziltivekimab’s ability to delay death or hospitalization from heart failure.
The original plan, according to the federal trials database, had been to read out Hermes in the first half of 2027. But Novo notified investigators on Friday that it was winding up both of the studies early.
The pharma made the decision after the trials’ data monitoring committee had assessed “the totality of the data,” Novo confirmed to Fierce.
Specifically, the committee had assessed the “low likelihood of a different outcome from Zeus”—a reference to a phase 3 trial in atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease and inflammation which missed its primary endpoint in July.
Before Zeus crashed down to earth, analysts at BMO had described ziltivekimab as “an important opportunity for Novo to extend its cardiovascular presence beyond obesity/diabetes,” while suggesting peak sales of around $3 billion.
Despite Novo execs having warned that the Zeus trial was always going to be a long shot, that study’s failure still caused some consternation, with Jefferies analysts reflecting at the time that the fail “calls into question whether IL-6/hsCRP reduction is a viable target in ASCVD, and by extension is a blow to the NLRP3 thesis, which sits upstream of IL-6.”
With Athena and Hermes also confirmed as duds, that thesis looks even further in doubt. Novo’s hopes for ziltivekimab now rest with Artemis, a phase 3 study in patients following an acute heart attack.
Novo told Fierce that Artemis will “continue as planned,” with a readout penciled in for the first half of next year. If Artemis also falls short, bringing to an end any hopes for ziltivekimab, it will wipe out one of Novo’s best shots at expanding beyond its narrow, if lucrative, comfort zone of obesity and diabetes.
Facts Only
* Novo Nordisk terminated two phase 3 trials for ziltivekimab: Hermes and Athena.
* Hermes enrolled 4,900 patients; Athena enrolled 673 patients.
* Both trials targeted patients with heart failure with mildly reduced or preserved ejection fraction.
* The primary endpoints were the delay of death or hospitalization from heart failure.
* The Hermes trial was originally scheduled for readout in the first half of 2027.
* A data monitoring committee assessed the totality of the data before the termination.
* The Zeus phase 3 trial in atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation missed its primary endpoint in July.
* The Artemis phase 3 study for patients following an acute heart attack remains active.
* Artemis results are expected in the first half of next year.
* BMO analysts previously estimated peak sales for ziltivekimab at approximately $3 billion.
Executive Summary
Novo Nordisk has terminated two phase 3 clinical trials, Hermes and Athena, for the IL-6 ligand ziltivekimab. These studies targeted patients with heart failure characterized by mildly reduced or preserved ejection fraction, with success measured by the drug's ability to delay death or hospitalization. The decision followed a data monitoring committee's assessment that the likelihood of a positive outcome was low, mirroring the results of the Zeus trial—a phase 3 study involving atherosclerotic cardiovascular disease and chronic kidney disease—which failed to meet its primary endpoint in July.
The failure of these trials challenges the prevailing scientific thesis that reducing IL-6/hsCRP is a viable target for treating cardiovascular disease. While analysts previously projected peak sales of $3 billion, seeing the molecule as a way for Novo Nordisk to diversify its portfolio beyond obesity and diabetes, those prospects have dimmed. The remaining viability of ziltivekimab depends on the Artemis study for acute heart attack patients, with results expected in the first half of next year.
Full Take
The strongest version of this narrative is a straightforward account of clinical failure: a pharmaceutical company is pruning a non-performing asset based on data-driven decisions to avoid wasted resources. It highlights the inherent risk of drug development and the fragility of biological hypotheses.
The narrative is driven by a "blockbuster" paradigm, where the value of a scientific discovery is measured primarily by its ability to expand a corporate "comfort zone" and hit multi-billion dollar revenue targets. The underlying assumption is that biological targets (like IL-6) should behave predictably across different cardiovascular manifestations. When they don't, the focus shifts from the clinical needs of the patients to the strategic "blow" dealt to the company's diversification efforts.
The implication is a narrowing of the therapeutic pipeline for heart failure patients. If the NLRP3/IL-6 thesis is indeed flawed, the cost is borne by patients who may have seen ziltivekimab as a potential lifeline. Conversely, the benefit is a redirection of scientific energy away from a failing path.
Patterns detected: none
Counterstrike Scan: A coordinated campaign to manipulate stock prices would use "catastrophic" language and speculate on a total collapse of the company's pipeline to trigger a sell-off. The current reporting remains grounded in trial data and analyst projections, lacking the manufactured panic of a market attack.
Bridge Questions:
1. Does the failure of ziltivekimab in these specific patient populations invalidate the IL-6 target entirely, or merely this specific molecule?
2. How much of the "consternation" regarding this failure is based on medical science versus investor expectations for portfolio diversification?
3. What alternative biological targets are being ignored while the industry focuses on the obesity/diabetes "comfort zone"?
Sentinel — Human
The text is a factual report detailing pharmaceutical trial outcomes and their subsequent impact on market expectations, exhibiting the structure of standard journalistic reporting.